Related Experiment Videos
IL-5: biology and potential therapeutic applications
1Department of Medicine, Brown University School of Medicine, Providence, RI 02912, USA. joel.weltman@brown.edu
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Interleukin-5 (IL-5) drives eosinophilic lung inflammation. Blocking IL-5 with monoclonal antibodies or antisense oligonucleotides offers a targeted approach to suppress this inflammation without glucocorticoid side effects.
Area of Science:
- Immunology
- Molecular Biology
- Respiratory Medicine
Background:
- Interleukin-5 (IL-5) is a key cytokine driving antigen-induced eosinophilic inflammation in the lungs.
- IL-5, produced by activated Th-2 cells, promotes eosinophil replication, differentiation, degranulation, survival, and adhesion.
- IL-5 exerts its effects through binding to the IL-5 receptor (IL-5R) on eosinophils, activating intracellular JAK-STAT signaling.
Purpose of the Study:
- To review the role of IL-5 in eosinophilic inflammation.
- To explore therapeutic strategies targeting IL-5.
- To evaluate the potential of anti-IL-5 reagents as alternatives to glucocorticoids.
Main Methods:
- Review of existing literature on IL-5 function and signaling.
- Analysis of studies investigating monoclonal antibodies (mAbs) against IL-5.
- Examination of research on antisense IL-5 oligonucleotides.
Main Results:
- IL-5 is crucial for eosinophil-mediated inflammation.
- Monoclonal antibodies against IL-5 effectively suppress eosinophilic inflammation.
- Antisense IL-5 oligonucleotides show promise for sequence-specific inhibition.
- The IL-5 gene promoter is down-regulated by glucocorticoids, suggesting alternative therapeutic targets.
Conclusions:
- Targeting IL-5 offers a specific method to control eosinophilic inflammation.
- Anti-IL-5 therapies, including mAbs and antisense oligonucleotides, present a viable alternative to glucocorticoids.
- Development of inhaled and topically applied anti-IL-5 agents is underway.